Radiopharmaceuticals are used for diagnosis of diseases of the central nervous and cardiovascular systems and for staging, restaging, and treatment planning for cancers. Nuclear biomarkers allow precise measurement of molecular pathways on a whole-body image upon administration of functional radiolabeled agents, and nuclear imaging agents have potential use in patient selection, pharmacokinetic, dosage-finding, and proof-of-concept studies. Nuclear imaging agents and hybrid instrumentation also provide sensitive and specific answers for differential responsiveness in therapeutic outcome.
This book serves as a reference for moving the discovery and development of radiopharmaceuticals from the workbench to clinical applications. It thus benefits not only clinicians but also translational research scientists—molecular biologists, chemists, imaging scientists, pharmaceutical developers, physicists, and support staff.
Dr. Tomio Inoue
President, Yokohama City University Medical Center
Dr. David J. Yang
Professor and Section Chief, Radiotheranostic Section,
Department of Cancer System Imaging,
Division of Diagnostic Imaging,
MD Anderson Cancer Center,
Consultant and Professor at The University of Tennessee Health Science Center,
Vice-president for Vyripharm Biopharmaceuticals
Dr. Gang Huang
Chairman, Institute of Nuclear Medicine,
Shanghai JiaoTong University School of Medicine